Sohm, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

Estimated Market Cap
$14,938,876 as of May 21, 2010
Outstanding Shares
237,125,016 as of Dec 31, 2009
Authorized Shares
1,000,000,000 as of Dec 31, 2009
Float(shares)
15,357,484 as of Dec 31, 2009
Number of Shareholders of Record
390 as of Dec 31, 2009
Number of Beneficial Shareholders
390 as of Dec 31, 2009

Manufacturing Hub

India has a significant share in the global generics market and is ranked third in the world. Three factors favoring the company’s manufacturing hub in India are a strong marketing set up, low prices and the advantage of using the English language. With domestic drug sales of almost $5 billion, Indian companies have also developed a considerable service industry for the global pharmaceutical market.

SOHM’s Branded Generic Pharmaceutical Line Expands to 280 Products

BUENA PARK, CA, May 21, 2010 (MARKETWIRE via COMTEX) — SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that its branded generic pharmaceutical line has expanded to 280 products. The Company expects partnerships and alliances to strengthen market penetration and revenue growth in key emerging markets in Africa, Latin America, and Southeast Asia.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc., stated, “Branded generics represent the most significant growth opportunity in emerging markets for pharmaceutical sales. Today, branded generics account for 25 percent of the global pharmaceutical market and have the majority of market share in the largest emerging markets. These target markets offer the highest global growth rates, continue to be very profitable and are largely underrepresented by large drug companies. We see huge potential for increased revenue and sales growth of the SOHM brand in 2010.”

SOHM India Expected to Report Record Revenue Growth in Generic Pharmaceutical Sales

BUENA PARK, CA, Apr 27, 2010 (MARKETWIRE via COMTEX) — SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that it expects to report record revenue growth for the 1st and 2nd quarters of 2010. The Company planned the rollout of its private label generic pharmaceutical product line in 2009, and has been aggressively focusing on expanding its market presence in India and select emerging pharmaceutical markets globally.
Shailesh Shah, Vice President for Corporate Strategy at SOHM, Inc. stated, “We are successfully penetrating our target markets in India and other emerging markets with our SOHM branded pharmaceuticals. The expansion of our staff and manufacturing facility in India has been fast paced and we are only in the beginning stages of scaling up operations. As momentum builds we find ourselves both delivering on our existing contracts and continuing to close new contracts. As we get closer to the middle of the year we are confident that revenue and sales growth will continue to increase at very impressive rates.”